MDT Q3 FY2026 Earnings: MiniMed Separation Costs Mask Strongest Growth in 10 Quarters

Medtronic delivered its strongest revenue growth in 10 quarters — $9,017 million, up 8.7% year-over-year — and beat non-GAAP EPS consensus by $0.02. The stock fell 3.2% anyway. Investors were looking past the headline and into the 10-Q filed February 24, where the cost of transformation comes into focus: $306-356 million in MiniMed separation costs repricing the income statement, a $1.146 billion antitrust verdict that the earnings press release never mentioned, and a Medical Surgical goodwill cushion of just 12% surfaced by the annual impairment test.

Quarterly thesis: This quarter shows Medtronic delivering accelerating revenue growth powered by a cardiovascular franchise where pulsed field ablation now dominates the EP market, which means the core business momentum is genuinely the strongest it has been in years, but front-loaded MiniMed separation costs ($156 million manufacturing termination plus $150-200 million in restructuring), a $1.146 billion antitrust verdict, and the thinnest goodwill cushion among its reporting units complicate the earnings trajectory for the next two to three quarters.

The paradox is real: Medtronic's operating performance is improving on nearly every organic metric that matters, yet the financial statements tell a story of compression. GAAP EPS fell 16.8% sequentially from $1.07 to $0.89. Gross margin dropped 200 basis points. Restructuring charges jumped from $13 million to $172 million in a single quarter. The question for investors is whether these are transformation costs with a clear endpoint — or the beginning of a margin structure that permanently resets lower as MiniMed separates and the remaining Medtronic absorbs stranded costs.

Cardiovascular Acceleration Is Carrying the Revenue Story

Medtronic's headline revenue growth of 8.7% deserves decomposition because the enterprise number obscures dramatically different trajectories across four segments. Cardiovascular — now 38.3% of total revenue — is doing the heavy lifting, and the gap between its momentum and the rest of the portfolio widened this quarter.

Cardiovascular revenue reached $3,457 million, up 13.8% year-over-year and accelerating from 10.8% Y/Y growth in Q2 — a 300 basis point sequential acceleration. Operating income hit $899 million at a 26.0% margin, up 50 basis points from Q2's 25.5%. This is the only segment that delivered both sequential revenue growth (+0.6% Q/Q) and sequential margin expansion.

The growth engine within Cardiovascular is Cardiac Ablation Solutions, which surged approximately 80% year-over-year with PFA (pulsed field ablation) now representing 80% of electrophysiology revenue. In the United States alone, Cardiac Ablation Solutions grew 137%. This is not a niche product line — it is rapidly becoming the standard of care in EP, and Medtronic's first-mover advantage in PFA is translating into a franchise-level growth vector.

The organic growth rates — stripped of currency and accounting adjustments — paint a more tempered picture. Enterprise organic growth was 6.0%, not 8.7%. Cardiovascular's organic growth was 10.6%, not 13.8% — a 320 basis point FX tailwind. The most striking gap is in Diabetes: reported growth of 15.4% versus organic growth of only 8.3%, a 710 basis point difference reflecting both favorable currency and the Italian payback accrual adjustments. This matters because the Diabetes segment is heading toward a standalone IPO, and investors pricing MiniMed need to distinguish underlying momentum from one-time tailwinds.

"The increase in net sales for the three and nine months ended January 23, 2026, as compared to the corresponding periods in the prior fiscal year, was driven primarily by growth in most businesses. In addition, the net sales increase was driven by impacts of foreign currency fluctuations and, for the nine months ended January 23, 2026, changes in estimates relating to our Italian payback accrual resulting from the two July 2024 rulings by the Constitutional Court and the Legislative Decree published by the Italian government in June 2025 and formalized into law in August 2025 for certain prior years since 2015."

Geographically, revenue is now evenly split: US revenue of $4,493 million (49.8%) versus Rest of World at $4,488 million (49.8%), with Ireland contributing $36 million. International grew faster at 11.4% versus 6.0% for the US — a dynamic that amplifies currency sensitivity heading into quarters where dollar strength could reverse these tailwinds. Medtronic's cardiovascular segment delivered $3,457 million in Q3 FY2026 revenue with Cardiac Ablation Solutions surging 80% year-over-year, making PFA the dominant growth driver that now accounts for 80% of electrophysiology revenue.

The MiniMed Separation Is Repricing the Income Statement

The most important paragraph in Medtronic's 10-Q isn't about revenue growth — it's a footnote explaining why gross margin compressed 200 basis points in a single quarter despite record top-line performance.

"In December 2025, management approved and committed to a plan to terminate a third-party manufacturing agreement within the Diabetes Operating Unit. In conjunction with this plan, the Company recorded pre-tax charges of $156 million, including $89 million recognized within cost of products sold related to asset write-offs and $67 million recognized within other operating expense (income), net related to contract termination costs."

Gross margin fell from 65.8% in Q2 to 63.8% in Q3 — a 200 basis point sequential decline. The $89 million COGS charge from the manufacturing termination accounts for approximately 100 basis points ($89M / $9,017M revenue). The remaining 100 basis points reflects a combination of product mix, foreign exchange effects, and pricing dynamics. Year-over-year, gross margin declined 119 basis points from 65.0% in Q3 FY2025, and the 8-quarter trend slope of -0.25% per quarter suggests a modest structural headwind even after normalizing for one-time charges.

But the $156 million manufacturing termination is only part of the separation cost story. In December 2025, the Board also approved restructuring actions to support the Medtronic/MiniMed separation, with expected pre-tax charges of $150-200 million to be incurred between Q3 FY2026 and finalization of the Transition Services Agreement. Restructuring charges jumped to $172 million in Q3 from just $13 million in Q2 — a 13-fold increase that overwhelmed the operating margin, which fell 260 basis points sequentially to 16.2%.

The GAAP-to-non-GAAP gap of $0.47 per share — 52.8% of GAAP EPS — warrants scrutiny. Amortization of intangible assets remains the dominant adjustment at $0.26 per share (55% of the bridge), a recurring acquisition-legacy cost that will persist for years. But the expanding item is restructuring: the ~$0.17 per share add-back in Q3 is up from approximately $0.05 a year ago, driven entirely by the MiniMed separation program. If the $150-200 million restructuring estimate is accurate, investors should expect two to three more quarters of elevated restructuring charges before this line normalizes.

GAAP EPS fell 16.8% sequentially from $1.07 to $0.89, while non-GAAP EPS of $1.36 grew 7.9% year-over-year from $1.26. The gap ratio actually improved versus Q3 FY2025 (52.8% versus 55.6%), meaning non-GAAP adjustments are growing more slowly than GAAP earnings on a year-over-year basis. No new adjustment categories were introduced — a positive signal that the reconciliation quality hasn't deteriorated despite the separation-related charges.

A notable development buried in the debt footnotes: in January 2026, Medtronic established a new five-year senior secured revolving credit facility for the Diabetes Operating Unit, which becomes available upon MiniMed Group's IPO completion. This was not in the Q2 10-Q and confirms the separation infrastructure is being built on schedule. Medtronic's Q3 FY2026 gross margin compression of 200 basis points to 63.8% was driven by a $89 million Diabetes manufacturing termination charge that accounts for approximately half the decline, with the remainder reflecting mix and currency headwinds.

The Risks the Earnings Release Didn't Mention

The 8-K earnings press release on February 17 told the story of record revenue and strong operational momentum. The 10-Q, filed seven days later on February 24, disclosed three material risk items that investors need to price in — one of which occurred before the 8-K was published.

The most significant: on February 5, 2026 — twelve days before the earnings release — a jury in the U.S. District Court for the Central District of California returned a verdict awarding Applied $382 million in damages, automatically trebled to $1.146 billion. The press release made no mention of it.

"On February 5, 2026, the jury returned a verdict in favor of Applied, awarding Applied $382 million in damages, which will be automatically trebled by the court. The Company believes the verdict is inconsistent with the law and the evidence and intends to seek relief through post-trial motions and, if necessary, appeal."

The $1.146 billion represents approximately 1% of Medtronic's market capitalization. Medtronic has not recorded any accrual, indicating management assesses the appeal has sufficient merit that the loss is not "probable" under ASC 450. But the math is sobering: if the full amount were accrued and tax-effected at the 18.1% Q3 effective rate, the after-tax impact would be approximately $940 million, or $0.73 per share — enough to wipe out 82% of Q3 GAAP earnings and exceed the entire non-GAAP adjustment bridge.

The second risk the 10-Q flagged is structural. Medtronic's annual goodwill impairment test — conducted in Q3 — revealed that the Medical Surgical reporting unit's fair value exceeded its carrying value by only 12%.

"The Medical Surgical reporting unit's fair value exceeded its carrying value by approximately 12%."

With $19.8 billion in allocated goodwill — the largest goodwill balance among the four reporting units — a 12% cushion is thin. Sensitivity analysis reveals that a 1% increase in the discount rate would narrow the cushion to just 3%, and a 5% reduction in projected cash flows would reduce it to 7%. The other three reporting units "materially exceeded their carrying values." Med Surg's revenue growth of 4.9% Y/Y was the slowest of any segment, and its operating margin compressed 110 basis points sequentially to 23.0%. If Med Surg's growth trajectory doesn't stabilize or improve, a goodwill impairment charge on a $19.8 billion balance could materially reset the GAAP earnings base.

The risk landscape wasn't entirely negative. The U.S. Court of Appeals for the Federal Circuit reversed the approximately $106 million Colibri patent infringement verdict in July 2025, ruling that Medtronic did not infringe. This eliminates a meaningful contingent liability. And the Diabetes pump retainer ring litigation improved — down to 4 lawsuits covering 12 individuals from 7 lawsuits and 14 individuals in Q2. Accrued litigation reserves held steady at $0.2 billion in Q3, down 50% from $0.4 billion at the start of the fiscal year. Medtronic's $1.146 billion antitrust verdict — disclosed in the 10-Q as a subsequent event but absent from the earnings press release twelve days later — represents the largest single contingent liability the company currently faces.

On the balance sheet, Medtronic made progress reducing debt: total debt fell from $29.1 billion to $28.1 billion, a $1 billion reduction driven primarily by repayments of Euro-denominated obligations. The company issued €1.5 billion in new Senior Notes maturing in 2031 and 2046 and used the proceeds to refinance near-term maturities, leaving only $191 million due within twelve months. The $3.5 billion credit facility remains fully undrawn.

Cash flow told a seasonal story. Q3 free cash flow of approximately $2,300 million (25.5% margin) surged from $457 million in Q2, but this reflects Medtronic's typical fiscal year pattern where collections normalize in Q3. Nine-month FCF of $3,341 million was up 7.2% year-over-year from $3,116 million, and the nine-month OCF-to-net-income ratio of 1.58x confirms strong cash earnings quality. Capital expenditures declined modestly to $444 million from $468 million in Q2, with R&D spending of $722 million holding steady at 8.0% of revenue.

What to Watch Next Quarter

Medtronic reiterated FY2026 guidance of approximately 5.5% organic revenue growth and non-GAAP diluted EPS of $5.62-$5.66 — notably below the broader Street consensus of approximately $6.12. With one quarter remaining, three metrics will determine whether the stock's 3.2% earnings-day decline was an overreaction or an early signal:

1. Gross margin recovery (target: >65%). If Q4 gross margin rebounds above 65%, it confirms the 200 basis point Q3 decline was predominantly the one-time $89 million COGS charge. If it stays below 64%, the 8-quarter trend slope of -0.25% per quarter becomes a structural narrative that reprices the earnings power baseline. Watch for continued MiniMed-related charges hitting COGS versus the $150-200 million restructuring that should flow through operating expenses.

2. MiniMed separation milestones. The January 2026 credit facility for the Diabetes Operating Unit is the first concrete financial infrastructure for the separated entity. Next quarter, investors should look for IPO timing specificity, the pace of restructuring charge recognition (how much of the $150-200 million program has been recognized), and whether the Diabetes segment can sustain its 15%+ reported growth rate as the Italian payback tailwind fades.

3. Antitrust appeal progress. Post-trial motions in Applied v. Medtronic will determine whether the $1.146 billion verdict is reduced, upheld, or potentially increased. A favorable motion could remove the overhang; an unfavorable outcome could force an accrual discussion with auditors. Monitor the case docket for rulings before the Q4 earnings release.

The bull case: Cardiovascular's PFA-driven acceleration sustains mid-teens growth, MiniMed separation costs peak in Q3/Q4 and then decline, the antitrust verdict is reduced on appeal, and Medtronic enters FY2027 with cleaner margins and a separated Diabetes entity that unlocks sum-of-the-parts value. The bear case: gross margin compression has a structural component beyond one-time charges, the $1.146 billion verdict is upheld, Med Surg's 12% goodwill cushion narrows further as growth decelerates, and the market assigns a permanent conglomerate discount to the remaining portfolio.

Frequently Asked Questions

How much did Medtronic's revenue grow in Q3 FY2026?

Medtronic reported Q3 FY2026 revenue of $9,017 million, up 8.7% year-over-year from $8,292 million and up 0.6% sequentially from $8,961 million in Q2. On an organic basis (excluding currency and the Italian payback accrual adjustment), growth was 6.0%. Management described this as the highest enterprise revenue growth in 10 quarters, with Cardiovascular (+13.8% Y/Y) and Diabetes (+15.4% Y/Y) driving the majority of the acceleration.

Why did Medtronic's stock fall after beating earnings estimates?

Despite beating revenue consensus by 1.35% ($9,017 million versus approximately $8,900 million expected) and adjusted EPS consensus by $0.02 ($1.36 versus $1.34), Medtronic shares fell approximately 3.2% because the company reiterated rather than raised full-year guidance. The FY2026 non-GAAP EPS range of $5.62-$5.66 sits well below the broader Street consensus of approximately $6.12, reflecting embedded tariff headwinds of $185 million and ongoing MiniMed separation costs that limit upside visibility.

What is the MiniMed separation and how much will it cost?

Medtronic is separating its Diabetes Operating Unit (MiniMed) into an independent public company through an IPO, announced in May 2025 with an 18-month timeline. Total separation costs disclosed to date include a $156 million manufacturing termination charge taken in Q3 FY2026 ($89 million in COGS for asset write-offs and $67 million in operating expenses for contract termination) plus an expected $150-200 million restructuring program approved by the Board in December 2025. The total program of $306-356 million will be incurred across multiple quarters through the finalization of the Transition Services Agreement. A new five-year secured revolving credit facility was established in January 2026 for the separated entity.

What is the $1.146 billion antitrust verdict against Medtronic?

On February 5, 2026, a jury in the U.S. District Court for the Central District of California awarded Applied $382 million in damages in an antitrust case (Applied v. Medtronic), which will be automatically trebled by the court to $1.146 billion. Medtronic has stated the verdict is "inconsistent with the law and the evidence" and plans to seek relief through post-trial motions and appeal. No accrual has been recorded, meaning management assesses the loss as not probable. If fully accrued at the 18.1% Q3 effective tax rate, the after-tax impact would be approximately $0.73 per share.

Why did Medtronic's gross margin fall 200 basis points?

Gross margin compressed from 65.8% in Q2 to 63.8% in Q3 FY2026, a 200 basis point sequential decline. The $89 million COGS charge from the Diabetes manufacturing agreement termination accounts for approximately 100 basis points of the decline ($89M / $9,017M revenue = 99 basis points). The remaining approximately 100 basis points reflects product mix shifts, foreign exchange effects, and pricing dynamics. Year-over-year, gross margin fell 119 basis points from 65.0% in Q3 FY2025, and the 8-quarter trend slope of approximately -0.25% per quarter suggests a modest ongoing headwind.

How is Medtronic's cardiovascular segment performing?

Cardiovascular is Medtronic's strongest growth engine, delivering Q3 FY2026 revenue of $3,457 million, up 13.8% year-over-year (10.6% organic). Cardiac Ablation Solutions grew approximately 80% Y/Y, with PFA now representing 80% of electrophysiology revenue. In the US market specifically, ablation solutions grew 137%. Operating margin improved 50 basis points sequentially to 26.0%, making Cardiovascular the only segment with both positive sequential revenue growth (+0.6% Q/Q) and margin expansion. The segment includes $30 million of accelerated amortization on certain Cardiovascular Portfolio intangible assets.

What is the Medical Surgical goodwill impairment risk?

Medtronic's annual goodwill impairment test, conducted in Q3, revealed that the Medical Surgical reporting unit's fair value exceeded its carrying value by only 12% — the tightest cushion among four reporting units, while the others "materially exceeded their carrying values." With $19.8 billion in allocated goodwill and total segment assets of $32.7 billion, a 1% increase in the discount rate would narrow the cushion to just 3%, and a 5% reduction in projected cash flows would reduce it to 7%. Med Surg's revenue growth of 4.9% Y/Y was the slowest of any segment and its operating margin compressed 110 basis points Q/Q.

What is the gap between Medtronic's GAAP and non-GAAP earnings?

The GAAP-to-non-GAAP EPS gap was $0.47 per share in Q3 FY2026, with GAAP EPS of $0.89 versus non-GAAP EPS of $1.36. This gap represents 52.8% of GAAP earnings. Amortization of intangible assets ($441 million, $0.26/share) accounts for 55% of the bridge and is a recurring, acquisition-legacy cost. Restructuring and manufacturing termination costs expanded to approximately $261 million (~$0.17/share) from approximately $67 million a year ago, driven by the MiniMed separation. Litigation charges of $62 million ($0.04/share) spiked from $10 million in Q3 FY2025. The gap ratio actually improved year-over-year (52.8% versus 55.6%), and no new adjustment categories were introduced.

How strong is Medtronic's free cash flow?

Q3 FY2026 free cash flow was approximately $2,300 million (25.5% margin), up sharply from $457 million in Q2 — reflecting Medtronic's typical fiscal year seasonality where Q3 is the strongest cash quarter. Nine-month FCF was $3,341 million, up 7.2% year-over-year from $3,116 million. Nine-month operating cash flow was $4,757 million with an OCF-to-net-income ratio of 1.58x, indicating strong cash earnings quality. Q3 standalone operating cash flow of $2,744 million was derived by subtracting the H1 figure of $2,013 million from the nine-month total of $4,757 million.

Methodology

Data sources: This analysis is based on Medtronic's Q3 FY2026 10-Q filed February 24, 2026 (SEC accession 0001628280-26-011107), the Q3 FY2026 8-K earnings release filed February 17, 2026, and MetricDuck's automated financial data pipeline covering standardized metrics, segment performance, and filing intelligence across five analytical passes.

Derived calculations: All derived figures (growth rates, margin changes, per-share impacts) use source data tagged throughout as [PIPELINE] (MetricDuck automated extraction), [FILING] (directly from SEC filings), or [DERIVED] (calculated from sourced inputs). Key formulas: Y/Y revenue growth = ($9,017M - $8,292M) / $8,292M = 8.74%; COGS charge margin impact = $89M / $9,017M = 99bps; antitrust after-tax impact = $1,146M × (1 - 0.181) / 1,284M shares = ~$0.73/share; GAAP-to-non-GAAP gap ratio = $0.47 / $0.89 = 52.8%.

Limitations: Quarterly analysis captures a single point in Medtronic's operating cycle. Organic growth rates are sourced from the 8-K earnings release, as the 10-Q does not separately disclose organic growth. The $89 million COGS charge margin impact assumes the charge is fully incremental to a normalized COGS base. The GAAP-to-non-GAAP bridge includes estimated per-share impacts for certain line items derived from the total pre-tax amount and estimated tax rates. Prior year comparisons use the press release figure of $8,292 million for Q3 FY2025 revenue rather than the pipeline's $8,578 million, as Medtronic's own Y/Y calculations use the former.

Disclaimer: This analysis is for informational purposes only and does not constitute investment advice. All data is sourced from public SEC filings and MetricDuck's automated pipeline. Investors should conduct their own due diligence and consult qualified financial advisors before making investment decisions. Past performance does not guarantee future results. Medical device industry earnings are subject to regulatory, litigation, and reimbursement risks that can materially alter forward-looking expectations.